Michele Tagliati, MD
Neurology · Los Angeles, CANPI 1134190457
Payments from drug & device makers
Across 674 payments — averaging $3675.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$686K
- Novo Nordisk$523K
- AbbVie$398K
- Biogen$386K
- Boston Scientific$211K
- Takeda Pharmaceuticals U.S.A., Inc.$104K
- plus $169K from 20 others
Across 2 payments — averaging $2402.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$5K
- Biogen$54
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 50 | $685,730 |
| Novo Nordisk | 14 | $523,359 |
| AbbVie(2 entities) | 91 | $397,834 |
| Biogen | 5 | $385,616 |
| Boston Scientific | 280 | $211,492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $104,108 |
| Medtronic(2 entities) | 65 | $44,805 |
| Abbott | 53 | $36,142 |
| Sage Therapeutics, LLC | 11 | $33,105 |
| Novartis | 2 | $23,800 |
| Genentech USA, Inc. | 8 | $7,476 |
| MDD US Operations, LLC | 15 | $5,448 |
| F. Hoffmann-la Roche AG | 2 | $5,123 |
| Tanabe Pharma America, Inc. | 9 | $4,644 |
| Acorda Therapeutics, Inc | 11 | $4,353 |
| Kyowa Kirin, Inc. | 1 | $2,250 |
| Merz Pharmaceuticals, LLC | 8 | $744 |
| Teva Pharmaceuticals USA, Inc. | 4 | $338 |
| Merz North America, Inc. | 4 | $281 |
| Insightec,inc | 1 | $146 |
| Acadia Pharmaceuticals Inc | 2 | $117 |
| Neurocrine Biosciences, Inc. | 1 | $111 |
| Life Molecular Imaging Ltd | 4 | $91 |
| Cala Health, Inc. | 1 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $1 |
How this compares
$2,477,158 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
- Lilyana AmezcuaLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.